TrialsgrambetaRCTs are beautiful

Obesity & weight management

Lifestyle (Look AHEAD), semaglutide (STEP, SELECT) and tirzepatide (SURMOUNT) trials in weight management.

Trials
3
Years
2013–2022
Sort
  • 2022SURMOUNT-1⁠Tirzepatide for obesityIn 2,539 adults with obesity without type 2 diabetes, tirzepatide 5, 10 or 15 mg weekly reduced body weight at 72 weeks compared with placebo.Read →
  • 2021STEP 1⁠Semaglutide for obesityIn 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.-14.9% vs -2.4%Read →
  • 2013Look AHEAD⁠Lifestyle interventionIn 5,145 patients with T2DM and BMI ≥25, intensive lifestyle intervention did not reduce cardiovascular events compared with diabetes support and education.HR 0.95Read →